WCN 2021 | Novel treatment strategies for NMOSD
Kazuo Fujihara, MD, PhD, Fukushima Medical University School of Medicine, Fukushima, Japan, gives an overview of novel treatment strategies for aquaporin-4 immunoglobulin G antibodies (AQP4-IgG)-positive neuromyelitis optica spectrum disorder (NMOSD), which notably include cell therapies such as hematopoietic stem cell transplantation (HSCT), chimeric antigen receptor (CAR)-T-cell therapy, and more recently, induction of tolerance using engineered dendritic cells (DCs). This interview took place during the XXV World Congress of Neurology.
Disclosures
Dr Fujihara reports personal fees and other support from Alexion, Chugai/Roche, Viela Bio (formerly MedImmune), Mitsubishi Tanabe, Biogen, Eisai, Novartis, Asahi Kasei Medical, Teijin, Takeda, Bayer, UCB, Abbvie, Japan Tobbaco, and Merck Biopharma; and grants from the Ministry of Education, Science and Technology of Japan and the Ministry of Health, Welfare and Labor of Japan.
